Silence Therapeutics (NASDAQ:SLN) Rating Reiterated by HC Wainwright

Silence Therapeutics (NASDAQ:SLNGet Free Report)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a report released on Friday, Benzinga reports. They currently have a $75.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 257.31% from the stock’s current price.

A number of other equities analysts have also recently issued reports on SLN. Chardan Capital reaffirmed a “buy” rating and issued a $42.00 price objective on shares of Silence Therapeutics in a research note on Friday, May 17th. Morgan Stanley reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of Silence Therapeutics in a research note on Monday, April 22nd.

Check Out Our Latest Research Report on SLN

Silence Therapeutics Trading Down 3.8 %

Shares of SLN stock opened at $20.99 on Friday. Silence Therapeutics has a 1 year low of $4.84 and a 1 year high of $27.72. The firm’s 50 day moving average is $21.89 and its 200-day moving average is $19.96. The firm has a market capitalization of $628.23 million, a price-to-earnings ratio of -18.09 and a beta of 1.38.

Silence Therapeutics (NASDAQ:SLNGet Free Report) last announced its earnings results on Thursday, May 16th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.18. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. The company had revenue of $15.73 million for the quarter, compared to analyst estimates of $4.53 million. On average, equities research analysts forecast that Silence Therapeutics will post -1.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Silence Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC bought a new position in shares of Silence Therapeutics during the fourth quarter worth $110,000. Lynx1 Capital Management LP bought a new position in shares of Silence Therapeutics during the third quarter worth $2,315,000. Parkman Healthcare Partners LLC boosted its position in shares of Silence Therapeutics by 20.8% during the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after purchasing an additional 40,063 shares in the last quarter. Vivo Capital LLC bought a new position in shares of Silence Therapeutics during the fourth quarter worth $8,862,000. Finally, Janus Henderson Group PLC bought a new position in shares of Silence Therapeutics during the first quarter worth $13,575,000. 98.73% of the stock is owned by institutional investors.

Silence Therapeutics Company Profile

(Get Free Report)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.

Featured Stories

Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.